CD274 and neoplasm: In light of unprecedented efficacy observed in multiple, historically difficult to treat tumor types using PD-1, PDL-1 and CTLA-4, inhibitors (CPIs), we now benefit from seven U.S. FDA approved drugs across sixteen indications between years 2011 and 2019 (Xiao et al., 2020).